Register Now

Forgotten Password?

Licensing agreement for maytansinoid Targeted Antibody Payload (TAP) technology

Companies: Abgenix
Amgen
ImmunoGen
Announcement date: Nov 19 2009
Related contracts: Collaborative R&D and licensing agreement for TAP prodrug technology for Xenomouse antigens
Licensing agreement for maytansinoid Targeted Antibody Payload (TAP) technology
Licensing agreement for TAP technology

Details

Announcement date: Nov 19 2009
Industry sectors: Bigpharma
Bigbiotech
Pharmaceutical
Biotech
Therapy areas: Oncology
Technology types: Antibodies
Biological compounds
Deal components: Licensing
Stages of development: Discovery
Preclinical
Geographic focus: Worldwide

Financials

Termsheet

Licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target.

This is the second such license to be taken by Amgen

Press Release

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 19, 2009-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen – the company licensed the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target in September 2009.

“Amgen undertook extensive diligence prior to taking the first license that enabled them to move ahead quickly with this second license,” commented Daniel Junius, President and Chief Executive Officer. “The commitment Amgen is showing to the development of significant new anticancer compounds using our TAP technology is impressive – both in the pace that they took this second license and in their thoroughness around product timelines.”

Both licenses were taken under a 2000 agreement that grants Amgen certain rights to test ImmunoGen’s maytansinoid TAP technology and to license rights to use it to develop products to individual targets on agreed-upon terms. Under the license announced today, ImmunoGen receives a $1 million upfront payment and is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. Amgen is responsible for the development, manufacturing and marketing of any products resulting from this license.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s TAP technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

Filing Data

Not available.

Contract

Not available.